MONTREAL, QUEBEC AND BOULDER, COLORADO--(Marketwire - October 10, 2007) - MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today announced the initiation of a Phase I clinical trial (Trial 011) evaluating MGCD0103, the Companies’ isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Taxotere® (docetaxel; Sanofi Aventis) in patients with solid tumors. Taxotere is an approved chemotherapy agent marketed for use in breast, lung, prostate, gastric and head and neck cancer.
